The term “the duration” immediately recalls the Second World War. Nobody had any idea when it would be over, and so discussions of a lot of World War II-related events and conditions prominently featured the phrase “for the duration” – as in great numbers of combat fatalities would continue to be reported for the duration, […]
Articles
This article was originally posted on August 27, when we first saw these ads circulating… apparently lots of folks missed it, and the ads are running hot and heavy again, so we’re re-posting it here to help answer a flood of new reader questions. The stock teased has popped 40-50% or so on the Stansberry […]
Newsletters have taken to hiring spokespeople for their promo videos, trying to give them that extra flash of veritas and professionalism and a nice “anchor voice”, and this time it’s actress and former journalist Suzanne Sena that Money Morning brings in to pitch their “super vaccine” idea… which doesn’t mean anything about the stock, of […]
This will surely not be the last time Doc Gumshoe turns his attention to the pandemic that is now imposing misery on many parts of the world. I need to acknowledge that when what was then generally called the Wuhan virus first came to my attention, I expressed the view that, despite the dire […]
This article was originally published on May 28, 2020, when we first saw these ads — they have recently been re-circulating as the June 30 date approaches and vaccine interest rises again. What follows has not been updated since May 28, though I did add an updated note at the bottom. We haven’t covered a […]
I’ve gotten a few questions about the latest Technology Profits Confidential (currently $79/yr) tease from Ray Blanco, so although it’s a few weeks old now, and started circulating right in the heat of the first coronavirus downturn in mid-March, I thought I’d take a look today. It is still a current ad, I got it […]
Ian Wyatt has been out over the past couple weeks with some “webinars” in which he talks up the coronavirus outbreak (for an hour!) and then ends his show with a tease about several “special reports” on the stocks he thinks will make you a lot of money as we fight COVID-19… and, of course, […]
Having just devoted an entire Doc Gumshoe piece to the notorious coronavirus (COVID 19), I’m going to make those coronavirus updates brief – it looks to me as though the news media is devoting a major part of its capacity to covering most aspects of this pandemic – and, yes, it now certainly looks like […]
That headline is not in my words, of course (that’s why I use those handy little quotation marks), but it’s the headline from the latest Nick Hodge ad that’s been getting a lot of attention from Gumshoe readers. Hodge is pitching this new device, which apparently faces a big moment on June 30, as a […]
Stansberry Venture is a high-end ($5,000/yr) newsletter that focuses on small “breakthrough” type companies, so far mostly in biotech and technology as far as I’ve seen. It’s the heir, roughly speaking, of Stansberry’s old Phase 1 newsletter that used to often pitch biotech, tech and junior mining stocks. It’s helmed by Dave Lashmet, who was […]
The latest screed from Danielle O’Dell for the Money Map Report is aimed at first getting you all fired up about Obamacare, in case you’re one of the seven people in the United States that doesn’t already have a strong opinion about that law’s impending enactment, and then, more importantly, at telling you that she’s […]
Patrick Cox has found a new home — he has issued many a tempting teaser campaign over the years, and I was wondering what had happened to him after leaving his Breakthrough Technology Alert in the hands of Ray Blanco this Summer. Well, I can stop wondering — he jumped to a new publisher and […]
And we’re back! Today, it’s a biotech teaser from Brian Hicks for Steve Christ’s The Wealth Advisory (we last looked at one of his a few months back, when he was predicting a big move in Geron by this Spring — that one’s still on the clock, so we’ll see). This time the tease is […]
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
Additional info on SNTA: Synta Pharmaceuticals (SNTA_), focuses on the discovery, development and commercialization of...
Analyst Rating Network shows 2 Sell Rating(s), 3 Buy Rating(s) for Synta Pharmaceuticals Corp. (NASDAQ:SNTA), with a Con...
Forgive me if it's been brought up before (It's not in the spreadsheet and I can't find it in this thread at least, but ...
As a peasant on this site, can I kindly if you are working on the analysis of Synta Pharmaceuticals (SNTA), Dr. KSS? Gl...
I have not seen ISR mentioned yet (IsoRay) and its brachytherapy with Cesium 131. I would love to know the good Dr. KSS...
Mr. Gumshoe, I believe you are correct with this one. I received the teaser email last week and came to the same conclu...